Australia caps semaglutide prescribing to 23 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The Ledger
Page 8 of 25 of this archive, newest first.
Page 8
How a claim degrades between the bench and the listing
The Journal does not treat a badge as evidence and states so wherever it reports one.
Sweden caps exenatide prescribing to 18 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
SURPASS-3 was built to answer the stopping question, and it did
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Japan caps exenatide prescribing to 16 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Reproducibility, measured rather than assumed
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
What a laboratory knows about the material it receives
Chain of custody, in a regulated setting, begins at sampling. Here it begins when the package arrives.
Poland caps liraglutide prescribing to 14 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Poland declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Side effects, cost, supply, target: four reasons with four trajectories
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
South Korea caps tirzepatide prescribing to 24 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Norway declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Three services, one lot, and a spread of two and a half points
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
The Netherlands declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The supply gap as a clinical event
A supply interruption is a discontinuation with no notice, no taper and no plan. That is a distinct clinical situation.
Canada declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Norway caps tirzepatide prescribing to 15 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
We split six vials four ways and posted them
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
Poland caps tirzepatide prescribing to 22 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The supply gap as a clinical event
Why the reason for stopping changes what happens afterwards.